37.Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, et al. A phase III randomized trial comparing inte rmittent versus continuous androgen suppression for patients Version Date: 12/5/17 Abbreviated Title : Enzalutamide in non-met CSPC 74with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 29: 2011 (suppl 7; abstr 3) 38.Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunothe r. 2011;60(2):197-206. Epub 2010/10/27. doi: 10.1007/s00262-010-0927-9. PubMed PMID: 20976449; PubMed Central PMCID: PMC3202216. 39.Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3-12. Epub 2007/11/17. doi: 4402269 [pii]10.1038/sj.cdd.4402269 [doi]. PubMed PMID: 18007663. 40.Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.